中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | HX126236 |
|---|---|
| 설명 |
Tecotabart (HX126236) is a research-grade recombinant antibody targeting Claudin-18. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG1-kappa |
| 타겟 | CLDN18.2, Claudin-18.2 |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | P56856-2 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | 2823329-10-6 |
| 배경 | Claudin-18 (CLDN18) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Tecotabart.
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
